Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-09-01
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will further evaluate the impact on delirium prevalence, stress level and general outcome parameters.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility Pilot of Bright Light in the Intensive Care Unit
NCT03568045
Improving Sleep Quality in ICU Patients
NCT02292134
Effect of Early Mobilization on Regional Lung Ventilation Assessed by EIT
NCT04081129
Sleep Bundle for Improving Sleep in ICU Patients
NCT03247062
Decreasing Trigger Sensitivity Could Assist PEEP to Further Improve Regional Ventilation Distribution
NCT03241654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The suprachiasmatic nucleus (SCN) in the hypothalamus serves as the master pacemaker that sets the timing of circadian rhythms by regulating neuronal activity. Its function is determined by environmental factors, especially visible light with a high content of blue light components. Light as a photoperiodic signal has a great impact on the regulation of the epiphyseal melatonin secretion and the entrainment of the day-night rhythm. As a result using light therapy to maintain or entrain circadian rhythm seems to be a promising approach to prevent delirium in critically ill patients. The specific light effect on the rhythmicity of the melatonin levels is to be examined in a randomized controlled study design, which includes the application of three different Light Scheduling Algorithms. In this context a highly specialized light ceiling was installed in two patient treatment rooms. A Light Scheduling Algorithm (LSA) consists of specified values for illuminance \[lux\] and correlated color temperature (CCT, \[kelvin\]) for different time points and durations within a 24-hour period. These values are calculated by assessment of photometric light measures with regard to visual light effects as well as non-image-forming functions at the patients bedside.
Patients will be randomly allocated in to 3 treatment groups: (1) LSA-1 (high circadian effective irradiances + blue Light Intervention), (2) LSA-2 (high circadian effective irradiances without blue light intervention) and (3) LSA-3 (standard irradiances, Control Group). All LSAs will be applied to the patient using VitalSky Advanced. For the purpose of validation of efficacy of specific light interventions, blood samples for measurement of melatonin concentration will be collected.
The temporal study sequence is defined by treatment days and measurement series periods (SMAP-1 to SMAP-4, Serum Melatonin Assessment Period). SMAP-1 starts on the first morning at 06:00 a.m. after study inclusion. SMAP-1 through SMAP-4 each define 24-hour periods in which the blood melatonin concentration is determined every 4 hours (6 am, 10 am, 2 pm, 6 pm, 10 pm, 2 am, 6 am). The SMAP-1 is intended to determine the patient's individual melatonin baseline. SMAP-2 to SMAP-4 start only when the patient has reached a stable level of wakefulness (RASS ≥-3 ). It can be assumed that the light intervention will only have an effect on melatonin balance from this level of wakefulness. A total of 4 SMAPs are planned per study patient.
Main Hypothesis:
Ventilated ICU patients receiving increased irradiance lighting may differ in the rhythmicity of serum melatonin concentrations and more frequently exhibit physiologic circadian melatonin secretions compared with patients receiving conventional irradiance lighting.
Secondary Hypotheses:
1. Ventilated intensive care patients receiving illumination with increased irradiance and phases of Blue-Enriched White light (BEW) differ in the rhythmicity of serum melatonin concentrations compared with patients receiving illumination with increased irradiance but without BEW.
2. Ventilated intensive care patients receiving illumination with increased irradiance and phases with BEW differ in the rhythmicity of serum melatonin concentrations compared with patients receiving illumination with conventional irradiance.
3. Ventilated intensive care patients receiving illumination with increased irradiance without phases with BEW differ in the rhythmicity of serum melatonin concentrations compared with patients receiving illumination with conventional irradiance.
4. Ventilated intensive care patients receiving increased irradiance lighting and periods of BEW have a lower incidence of delirium than patients receiving conventional irradiance lighting.
5. Ventilated intensive care patients receiving increased irradiance lighting and periods of BEW have lower delirium severity than patients receiving conventional irradiance lighting.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LSA-1
Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances + Blue Enriched Light episodes
Dynamic Light Therapy Device, LSA-1
Dynamic Light Therapy
LSA-2
Light Scheduling Algorithm-2 (LSA-2): High circadian effective irradiances without Blue Enriched Light episodes.
Dynamic Light Therapy Device, LSA-2
Dynamic Light Therapy
LSA-3
Light Scheduling Algorithm-3 (LSA-3): Irradiance levels comparable to conventional hospital lighting (control group).
Dynamic Light Therapy Device, LSA, 3
Dynamic Light Therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dynamic Light Therapy Device, LSA-1
Dynamic Light Therapy
Dynamic Light Therapy Device, LSA-2
Dynamic Light Therapy
Dynamic Light Therapy Device, LSA, 3
Dynamic Light Therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female patients with age ≥ 18 years
* Expected intensive care unit stay ≥ 5 days
* Invasive mechanical ventilation or non-invasive mechanical ventilation (with positive ventilation pressure \> 6 hours/day or high flow \>30 liters) on the day of ICU admission
Exclusion Criteria
* Patients with psychiatric diseases
* Patients with a history of stroke and known severe residual cognitive deficits
* Patients with a history of cardiopulmonary arrest or pulseless electric activity with cardiopulmonary resuscitation followed by therapeutic hypothermia during entire hospital stay
* Analphabetism
* Anacusis or Hypoacusis with hearing aid device, Amaurosis
* Lacking willingness to save and hand out data within the study
* Accommodation in an institution due to an official or judicial order
* History of sleep-related breathing disorders
* History or suspicion of hypoxic brain damage
* History or suspicion of elevated intracranial pressure in the last 7 days before study inclusion
* Patients with an open chest after cardiac surgery
* Patient has a power of attorney or patient's provision, where he/she refuses participation in any clinical trial
* The informed consent of the patient or the subject's legally acceptable representative can't be obtained in time
* Severe eye diseases
* History of photoallergic reactions
* History of visually triggered seizures
Termination criteria:
Under the following conditions, premature withdrawal of a Patient from the study according to the termination criteria will occur:
* Personal request of the patient/caregiver/authorized representative.
* Any other situation in which, in the opinion of the study physician, continued participation in the clinical trial is not in the best interest of the of the patient
* Subsequent occurrence of an exclusion criterion
Premature termination of the study or discontinuation of the entire study may be considered because of the following circumstances:
* Decision of the principal investigator in case of unacceptable risks under Benefit-risk consideration
* New (scientific) findings during the term of the clinical study that may compromise the safety of the study participants (positive risk-benefit balance no longer given).
18 Years
110 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alawi Luetz
Prof. Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité - Universitätsmedizin Berlin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website of Research Group
Website of Department
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20018170
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.